Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc.

Overview
Date Founded

2011

Headquarters

35 CambridgePark Drive, 4th Floor, Cambridge, MA, 02140, USA

Type of Company

Public

Employees (Worldwide)

83

Industries

Biotechnology

Company Description

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425 and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Website

http://www.syros.com

Contact Data
Trying to get in touch with decision makers at Syros Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
In The News
Business Wire
January 11, 2021
Syros Announces Strategic Priorities and Expected Milestones; On Track to Initiate Three Clinical Trials in 2021 Across Franchise of Targeted Hematology Therapies, Including Phase 3 Trial for SY-1425 in MDS; Additional Data from Dose-Escalation Trial of S
Business Wire
January 7, 2021
Syros to Present at 39th Annual J.P. Morgan Healthcare Conference
Nasdaq
December 24, 2020
Top ETF of December & Its Best Stocks
ENP Newswire
December 9, 2020
-Syros Closes $ 90.5 Million Strategic Financing
Business Wire
December 5, 2020
Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies; Oral Arsenic Trioxide has Potential to Reduce Treatment Burden of Standard-of-Care Regimen that Cures

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.
Executives & Employees
See More
Nancy Simonian

President & Chief Executive Officer

Joseph J. Ferra

Chief Financial Officer

Kristin Stephens

Chief Development Officer

Eric R. Olson

Chief Scientific Officer

David A. Roth

Chief Medical Officer

Gerald E. Quirk

Chief Legal & Administrative Officer

Jeremy P. Springhorn

Chief Business Officer

Nathanael Gray

Co-Founder

Alfred J. Mandel

Investor

Naomi Aoki

Head-Media Relations

Board of Directors
Peter Wirth

Former Executive Chairman at ZappRx, Inc.

Phillip Sharp

Co-Founder at Alnylam Pharmaceuticals, Inc.

Srini Akkaraju

Founder at Samsara Biocapital LLC

Marsha Fanucci

Former Chief Financial Officer & Senior Vice President at Takeda Oncology Co.

Amir Nashat

Partner at Polaris Partners

Nancy Simonian

President & Chief Executive Officer at Syros Pharmaceuticals, Inc.

S. Gail Eckhardt

Chair, Department of Oncology at University of Texas at Austin - Dell Medical School

Richard A. Young

Director at Camp4 Therapeutics Corp.

Mark Alles

Former Chairman & Chief Executive Officer at Celgene Corp.

Trending People
Db X-trackers Ii Sicav - Singapore Dollar Cash Ucits Etf
Wednesday March 03, 2021 Q & M Dental (QC7:59.50c) increases 1.7% strengthening... - News Bites - Asia: Singapore
H. C. Wainwright & Co. LLC
SQZ Biotech to Present at H.C. Wainwright Global Life Sciences Conference - Business Wire
Renesas Electronics Corporation
Semtech and DTDS Accelerate IoT Development With New Module; The 622 Module is L... - Business Wire
Apollo Global Management, Inc.
Las Vegas Sands to sell properties for about $6.25 bln - Nasdaq
IHS Markit Ltd.
More Rate Scares Ahead for Stocks - The Wall Street Journal
Trending Organizations
Db X-trackers Ii Sicav - Singapore Dollar Cash Ucits Etf
Wednesday March 03, 2021 Q & M Dental (QC7:59.50c) increases 1.7% strengthening... - News Bites - Asia: Singapore
H. C. Wainwright & Co. LLC
SQZ Biotech to Present at H.C. Wainwright Global Life Sciences Conference - Business Wire
Renesas Electronics Corporation
Semtech and DTDS Accelerate IoT Development With New Module; The 622 Module is L... - Business Wire
Apollo Global Management, Inc.
Las Vegas Sands to sell properties for about $6.25 bln - Nasdaq
IHS Markit Ltd.
More Rate Scares Ahead for Stocks - The Wall Street Journal
Paths to Syros Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Syros Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden
Bain Capital Life Sciences LP

Bain Capital Life Sciences is an active manager which invests in companies located in across the globe. The firm follows of biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies. Bain Capital Life Sciences provides investments in the form of inflection capital, growth capital, fallen angels and larger private equity types.

Details Hidden
Flagship Pioneering

Flagship Pioneering seeks investment opportunities in companies located globally. The firm focuses on companies operating in the fields of therapeutics, life science tools & diagnostics, and bioenergy or cleantech. It provides financing for seed, early, and later-stage capital requirements. It acts as a lead investor. It also makes co-investments.

Details Hidden
Samsara Biocapital LLC

Samsara Biocapital invests in companies located in the US. They targets companies operating in the fields of biotechnology and pharmaceuticals. They provide financing for early stage capital requirements.

Recent Transactions
Details Hidden

Syros Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Syros Pharmaceuticals, Inc. issued . USD Common Stock and Warrants

Details Hidden

Syros Pharmaceuticals, Inc. issued . USD Common Stock

Insider Transactions
Details Hidden
Richard A. Young

Details Hidden
Nancy Simonian

Transaction Advisors
Escrow Agent
Computershare Trust Co., NA

Advised onSyros Pharmaceuticals, Inc. issued USD Common Stock

Underwriter
Cowen and Company LLC

Advised onSyros Pharmaceuticals, Inc. issued USD Common Stock

Underwriter
JMP Securities LLC

Advised onSyros Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor
Cynthia T. Mazareas

Advised onSyros Pharmaceuticals, Inc. issued USD Common Stock

Professional
Neil Riley

Advised onSyros Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor
Steven Singer

Advised onSyros Pharmaceuticals, Inc. issued . USD Common Stock and Warrants
Advisors & Consultants
Advisor
Hannah Deresiewicz

Professional at Blueprint Medicines Corp.
Clients
Incyte Corp.

Incyte's vision is to become a leading drug discovery, development and commercial company by building a proprietary product pipeline of novel small molecule drugs for serious unmet medical needs. We have experienced management, discovery, clinical development and commercial teams. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders. Our pipeline is focused on oncology and inflammation and includes compounds in various stages of development. Our lead product, Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the United States for the treatment of intermediate or high-risk myelofibrosis (please see Full Prescribing Information and Important Safety Information for Jakafi) and is in development as a potential treatment for other cancers. We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. Through strategic collaborations with Novartis and Eli Lilly, we are advancing the global development of two of our JAK1 and JAK2 inhibitor programs. Incyte's corporate headquarters is located in Wilmington, Delaware

Global Blood Therapeutics, Inc.

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.
Key Stats and Financials As of 2019
Market Capitalization
$671M
Total Enterprise Value
$212M
Earnings Per Share
$-1.88
Revenue
$1.98M
Net Profit
$-75.4M
EBITDAMargin
-3,785.02%
Total Debt
$25.9M
Total Equity
$79.2M
EBITDA
$-75M
Debt TEV
0.12x
TEVNet Income
-2.81x
Enterprise Value / Sales
107.04x
Three Year Compounded Annual Growth Rate Of Revenue
84.22%
Investors
Details Hidden
Flagship Pioneering

Flagship Pioneering seeks investment opportunities in companies located globally. The firm focuses on companies operating in the fields of therapeutics, life science tools & diagnostics, and bioenergy or cleantech. It provides financing for seed, early, and later-stage capital requirements. It acts as a lead investor. It also makes co-investments.

Details Hidden
J. P. Morgan Investment Management, Inc.

JPMIM utilizes different methods of analysis that are tailored for each of the investment strategies they offer their clients. They use different methods of analysis and investment strategies in formulating investment advice or managing assets. The firm employs global fundamental research, quantitative valuation tools and bottom-up portfolio construction methods. Research analysts evaluate the US market by sector, while globally-based portfolio managers and analysts cover the international capital markets. JPMIM integrates the skills of their research analysts with those of experienced portfolio managers and economists to leverage information and choose the most fundamentally attractive investments.

Details Hidden
Casdin Capital / Private Equity

Casdin Capital / Private Equity/ invests in companies located in the US. The firm targets companies operating in the fields of life sciences and healthcare industry. It provides financing for early stage capital requirement

Suppliers
RaQualia Pharma, Inc. Pharmaceuticals | Nagoya, Japan

RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. Its medicines focus on pain, gastrointestinal, auto-immune diseases, inflammation, cancer, and Alzheimer's. Its products include Anidulafungin, Dalbavancin, Ziprasidone, 5-HT4 Partial Agonist, and 5-HT2B Antagonist. The company was founded on February 19, 2008 and is headquartered in Nagoya, Japan.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Agios Pharmaceuticals, Inc. Pharmaceuticals - Cambridge, Massachusetts

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Exelixis, Inc. Biotechnology - South San Francisco, CA

Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. In advancing our first product, COMETRIQ, from discovery to market, we have established an effective and integrated infrastructure that encompasses the entire biopharmaceutical development continuum. We are committed to excellence in all aspects of our work and are dedicated to improving the care and outcome of cancer patients.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Syros Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Syros Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Syros Pharmaceuticals, Inc..